Does the Antitumor Necrosis Factor-α Therapy Decrease the Vertebral Fractures Occurrence in Inflammatory Bowel Disease?

BACKGROUND/OBJECTIVE: Osteoporosis and osteoporotic fracture risk are extraintestinal manifestations of the inflammatory bowel disease, whose etiopathogenic mechanisms have not been determined yet. Anti-tumor necrosis factor (TNF)-α are used in treatment of inflammatory bowel disease (IBD), but it is unknown if they play a role in osteoporotic fracture prevention. The objective of this study was to know if anti-TNF decreases fracture risk or modifies bone mineral density. To determine the possible risk factors associated with fractures, and assess the incidence of vertebral fractures in IBD patients. METHODS: Longitudinal prospective cohort study (7 yr of follow-up); which included 71 IBD patients, 23 received anti-TNF-α; the remaining 48 received conventional treatment, constituted the control group. Patients participated in a questionnaire which gathered risk factors associated with the development of osteoporosis and fractures. Radiographs of the dorsolumbar-spine were performed and also a bone density measurement. Their biochemical and bone remodeling parameters were determined. RESULTS: Although patients who did not receive anti-TNF-α, suffered more fractures but biologic therapy did not reduce the risk of new vertebral fractures. The increase of bone mass was significantly higher the group treated with anti-TNF-α. The increase in the lumbar spine was of 8% and in the femoral neck was of 6.7%. The only determinant factor for the incidence of vertebral fractures was a history of previous fractures (odds ratio of 12.8; confidence interval 95% 2.37-69.9; p = 0.003). The incidence of vertebral fractures in IBD patients was considerably high: 26.7/700 patient-yr. CONCLUSIONS: Anti-TNF-α, although increased bone mass in these patients, did not reduce the risk of new vertebral fractures. In this study, patients with IBD have a considerably high incidence of fractures. Only the existence of previous vertebral fractures was a predictive factor for consistent fractures.

[Do men and women have the same risk factors for hip fractures?]. / ¿Se fracturan la cadera los hombres y las mujeres ante los mismos factores de riesgo?

BACKGROUND AND AIMS: Osteoporosis has been traditionally considered as a disease in women. However, it is now known that this condition is also important in men. It is a multifactor condition whose main independent risk factor to suffer fractures, in general, and those of the hip, specifically, is bone mass. Nonetheless, there are other independent risk factors of importance. This study has aimed to study if men and women suffer hip fractures with the same bone mass and if they have the same risk factors associated to this condition. PATIENTS AND METHODS: We studied 105 patients with non-traumatic hip fracture and 68 healthy controls. The different risk factors were analyzed, including clinical data, lifestyle, analytic data, data related to bone metabolism and sex hormones as well as a complete bone evaluation. RESULTS AND CONCLUSIONS: Hip bone mass density (BMD) values are the main risk factor for osteoporotic fractures in both genders. These values are comparable when expressed in terms of volumetric density. In women, risk factors that determine the appearance of fractures are previous non-traumatic fractures when they are older than 50 years, total hip BMD, serum calcium levels and thiazide intake while in men only total hip BMD reaches statistical significance.

[Phosphorus-calcium metabolism in children under prolonged treatment with anticonvulsants. (II)]. / Metabolismo fosfocálcico en niños con tratamiento prolongado anticonvulsivo. (II).

Comparative assessments were made regarding the effects of prolonged administration of anticonvulsant drugs (phenobarbital, carbamazepine, valproate and polytherapy) on the different biochemical parameters related to phosphocalcium metabolism, in 98 children between 1 and 14 years. The most patent effect was on the levels of 25-Hydroxycholecalciferol which went down significantly (p = 0.0001) in children treated with phenobarbital (34.5 +/- 17 ng/ml) or polytherapy (28.4 +/- 18 ng/ml) in relation to those treated with carbamazepine (49.2 +/- 15 ng/ml) or valproate (43.1 +/- 15 ng/ml) and to control group (45.9 +/- 13 ng/ml). The alkaline phosphatase has been found significantly higher among those treated with phenobarbital, carbamazepine and polytherapy, evidencing significant differences in relation to those treated with valproate and to control group (p less than 0.05). For calcium, parathyroid hormone and osteocalcine levels no differences were found in the different drugs, nor with control group. Depending on the duration of treatment there was a significant reduction (p = 0.02) in the levels of 25-Hydroxycholecalciferol in children treated over 3 years, but no difference for calcium, phosphorous, alkaline phosphatase and PTH under this parameter.

[Intraerythrocyte levels of glucose-6-phosphate dehydrogenase in patients with essential arterial hypertension and persons with normal blood pressure. Modifications after nifedipine therapy]. / Niveles intraeritrocitarios de glucosa 6 fosfato deshidrogenasa en pacientes con hipertensión arterial esencial y sujetos normotensos. Modificaciones después del tratamiento con nifedipina.

We evaluate the levels of intra-erythrocytes glucose-6-phosphate-dehydrogenase (G6PD) in a group of 50 patients with essential blood hypertension (EBH) (214.76 +/- 38.31 mU/ml) and in a group of 50 healthy persons (130.11 +/- 49.50 mU/ml) (p minor of 0.0005). At the same time, we have analysed the intraerythrocyte levels of G6PD of 34 healthy sons and daughters of hypertensive parents, detecting high levels in 13 of them. We observed a significant decrease of G6PD after the therapy with nifedipine in 20 hypertensive patients (p less than 0.0005). We conclude that measurement of G6PD enzyme activity can prove to be a good marker of essential hypertension. This change occurs at an early stage and is noticeable in high risk persons with family predisposition. It is possible to modify levels by working on cation changes through membrane cells by calcium-antagonist.

[Intestinal calcium and vitamin D absorption in essential arterial hypertension]. / Absorción intestinal de calcio y vitamina D en la hipertensión arterial esencial.

The intestinal absorption of calcium and seric levels of calcifediol and calcitriol were studied in 27 patients with essential blood hypertension (BH) and 20 normal patients in a control group. The hypertensive patients were divided in three groups depending on the plasmatic renin activity (PRA), (high, normal, low). We found a significantly higher rate of intestinal calcium absorption in the group of patients with BH and low PRA than in the control group (22.73 +/- 19.05 and 10.7 +/- 17.13% respectively) (p less than 0.025). The seric levels of calcitriol (1,25 (OH) 2D3) were significantly higher in the group of patients with hypertension and low PRA than in the control group (48.16 +/- 5.25 and 33.13 +/- 2.9 pg/ml respectively) (p less than 0.025). The seric levels of calcifediol (25-OH-D3) were significantly lower in low PRA patients than those patients in the control group (12.37 +/- 2.44 and 21.94 +/- 2.82 ng/ml respectively) (p less than 0.025). We concluded that patients with essential blood hypertension and low PRA have significantly lower calcitriol levels than any other group, probably conditioning the greater intestinal calcium absorption shown in this group.

[Effect of an oral calcium supplement in the treatment of slight-to- moderate essential arterial hypertension]. / Influencia de un suplemento oral de calcio en el tratamiento de la hipertensión arterial esencial ligera-moderada.

51 patients with mild essential hypertension (EH) were randomly divided into two groups; the first group (31 patients) was treated with 1 g. of oral calcium during a period of 8 weeks; the second group received a placebo. The treated with calcium showed a significant decrease in blood pressure (BP), the maximal reduction being of 6 mm Hg in the systolic pressure (SBP) and 3 mm in the diastolic (DBP) at the end of the 8th week. We found a substantial positive relationship between the decrease in SBP and seric renin activity (p less than 0.05), as well as a significant negative relationship (p less than 0.05) between DBP and the seric level of parathyroid hormone (PTH). During the administration of the oral calcium supplement, the BP decreased in an inverse proportion to the plasmatic renin and seric level of PTH.